Compare WIMI & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIMI | IXHL |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 37.0M |
| IPO Year | 2019 | 2024 |
| Metric | WIMI | IXHL |
|---|---|---|
| Price | $1.52 | $4.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 100.7K | ★ 295.6K |
| Earning Date | 04-24-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $0.16 |
| 52 Week High | $5.65 | $6.39 |
| Indicator | WIMI | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 60.31 |
| Support Level | N/A | $2.68 |
| Resistance Level | $1.72 | $4.22 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 33.57 | 82.73 |
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.